Tempest Therapeutics, Inc.

Analysis for Ticker: TPST

Tempest Therapeutics Inc is a biotechnology company that researches small molecules and cell therapies like amezalpat and TPST-2003 to treat cancer, but the laboratory is actually a machine for manufacturing paper. Over its existence, this entity has built a historical deficit of 233,4$ million while generating zero revenue from its clinical programs. The math is a disaster because the company burns millions of dollars to pay for research it cannot afford, then prints millions of new shares to pay its own bosses and outside lenders. This is like trying to fix a leaky bucket by drilling more holes in it to catch the water; every time they print more shares, the pieces of the company held by regular people get smaller and smaller until they are almost worthless.